We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.ContinueLearn More X
Phillips-Medisize Corporation announced today the formation of an advisory board to guide and counsel the company on its continued growth strategy and future opportunities. The advisory board will work closely with the executive team; the first two members appointed are Luc Vierstraete and Charles Goldstein.
Mr. Vierstraete brings a broad range of international healthcare industry experience, which he acquired during his nearly 40 years with Roche and Schering-Plough. Having worked in eight countries and three continents, he has the ability to engage with stakeholders and complex global leadership teams in diverse cultural environments. Most recently as global head of Roche Diabetes Care Business Unit, Mr Vierstraete was responsible for the total value chain from technology and R&D to operations and marketing/sales. During his time in this position, the company regained the worldwide number one position in glucose monitoring. During his tenure with Roche, he also served as general manager of several other Roche facilities throughout North America, Europe and Asia.
"Luc’s intimate understanding of the challenges faced by commercial franchise leaders in biopharmaceutical companies will strengthen our ability to understand and solve their key drug delivery and connected health challenges. This is the latest investment in partnering with our customers, following our acquisition of Medicom Innovation Partner, a leader in device strategy and connected health solutions," said Matt Jennings, chairman, CEO and president, Phillips-Medisize.
Mr Vierstraete commented, "I’m pleased to support Phillips-Medisize as a member of the advisory board. I have enjoyed a productive professional relationship with the team at Phillips-Medisize for many years, so this is a natural evolution of our relationship."
Dr. Goldstein brings over 30 years of experience in the medical/biopharma product and technology development arena. Most recently, as Senior Vice President/Chief Scientific Officer Greater Asia, he was responsible for the strategy and global performance of BD’s regional R&D operations in Asia with the goal to enhance the companies’ growth in emerging countries via market appropriate solutions. Dr. Goldstein has held other executive leadership roles at BD where he engaged in venture investing, start-up incubation, technology development and product commercialization efforts.
"Charles’ distinguished career and experience in technology and product development will be a valuable asset to Phillips-Medisize as we continue to address increasingly complicated drug delivery, consumable diagnostics and medical/surgical product challenges. Our teams will benefit from his expertise in product commercialization and finding and nurturing new technologies," commented Matt Jennings, chairman, CEO and president, Phillips-Medisize.
Dr Goldstein noted, "I look forward to working with a leader in product and device design and development. The breadth of technical and engineering challenges the company is tackling for customers is remarkable, and represents a world-class portfolio of emerging solutions in drug delivery and point-of-care diagnostics."